The Combined Anti-Aging Effect of Hydrolyzed Collagen Oligopeptides and Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells on Human Skin Fibroblasts

Autor: Huimin Zhu, Xin Guo, Yongqing Zhang, Ajab Khan, Yinuo Pang, Huifang Song, Hong Zhao, Zhizhen Liu, Hua Qiao, Jun Xie

Publikováno v: Molecules, Vol 29, Iss 7, p 1468 (2024)

Stem cell-derived exosomes (SC-Exos) are used as a source of regenerative medicine, but certain limitations hinder their uses. The effect of hydrolyzed collagen oligopeptides (HCOPs), a functional ingredient of SC-Exos is not widely known to the gene

Externí odkaz: https://doaj.org/article/c9c22341ab8e4b3292d1e9daca6b8a67

Population Pharmacokinetic and Exposure–Response Analyses for Efficacy and Safety of Risankizumab in Patients With Active Crohn's Disease

Autor: Ahmed Abbas, Suleiman, Aline, Goebel, Sumit, Bhatnagar, Ronilda, D'Cunha, Wei, Liu, Yinuo, Pang

Publikováno v: Clinical Pharmacology & Therapeutics. 113:839-850

The population pharmacokinetics (PK) of risankizumab, and exposure-response relationships for efficacy and safety in subjects with Crohn's disease (CD), were characterized using data from phase 2 and 3 studies, to support dosing regimen selection. A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13a802cd15b9ac1e0cba70ef5354705f
https://doi.org/10.1002/cpt.2831

Efficacy and Safety of ABBV ‐3373, a Novel Anti–Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody–Drug Conjugate, in Adults with Moderate‐to‐Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double‐Blind , Active‐Controlled Proof‐of‐Concept Phase IIa Trial

Autor: Frank Buttgereit, Jacob Aelion, Bernadette Rojkovich, Anna Zubrzycka‐Sienkiewicz, Su Chen, Yang Yang, Dilek Arikan, Ronilda D'Cunha, Yinuo Pang, Hartmut Kupper, Timothy Radstake, Howard Amital

Publikováno v: Arthritis & Rheumatology.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c3a2cdaea2b5cb29e004036b46c9ab02
https://doi.org/10.1002/art.42415

Pharmacokinetic Comparability of Risankizumab Formulations in Prefilled Syringe and Auto-injector for Subcutaneous Injection

Autor: Sai Nudurupati, Jasmina Kalabic, Ling Cheng, Yinuo Pang, Hoi-Kei Lon, Ralf Loebbert, Rachel Duan

Publikováno v: Clinical Therapeutics. 43:629-636

Purpose Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that inhibits the p19 subunit of interleukin 23 from interacting with its receptor for the treatment of moderate to severe plaque psoriasis. The aim of this Phase I biopharmace

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1deee5836058c99a14c3754d8428e171
https://doi.org/10.1016/j.clinthera.2021.01.009

Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study

Autor: Marc Ferrante, Arthur Kaser, Geert R. D'Haens, Wan-Ju Lee, Julián Panés, Xiaomei Liao, Olivier Dewit, Brian G. Feagan, Filip Baert, Jasmina Kalabic, W. Rachel Duan, Kori Wallace, Yinuo Pang, Dawn Gustafson, Edouard Louis

Publikováno v: Journal of Crohn's & colitis, 15(12), 2001-2010. Elsevier
Journal of Crohn's & colitis, Vol. 15, no.12, p. 2001-2010 (2021)
Journal of Crohn's & Colitis

Background and Aims Risankizumab, an interleukin-23 antibody, demonstrated efficacy and acceptable safety in a phase 2 study of patients with moderate-to-severe refractory Crohn’s disease. This open-label extension investigated the long-term safety

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e418780af15ef3e836bc2ac0db175f7
https://pure.amc.nl/en/publications/longterm-safety-and-efficacy-of-risankizumab-treatment-in-patients-with-crohns-disease(2efdb272-1af3-47e5-a541-ad43af36fa8f).html